Bafna Pharmaceuticals Limited — Outcome of Board Meeting

Bafna Pharmaceuticals Limited has informed exchanges that its board has approved the unaudited financial results for the quarter and half-year ended September 30, 2026. The company has also filed the Limited Review Report from its statutory auditors along with this regulatory filing. This update marks the formal disclosure of the company's performance metrics for the first half of the financial year.

This announcement is significant for investors as it provides the first official data on the company's operational health and profitability during this period. The unaudited figures offer a preliminary look at the company's trajectory, allowing stakeholders to assess its current financial standing before the final audited statements are released. This information is crucial for evaluating the company's performance against market expectations.

Investors should monitor the specific revenue and profit figures disclosed in the report to gauge the company's growth momentum. Additionally, keeping an eye on the auditors' comments in the Limited Review Report will provide further context on the company's financial health. Market participants will likely focus on whether the results align with or deviate from analyst estimates.